Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$3.69 - $5.35 $39,881 - $57,822
-10,808 Reduced 4.93%
208,448 $956,000
Q1 2023

May 15, 2023

BUY
$4.03 - $5.89 $154,941 - $226,452
38,447 Added 21.26%
219,256 $1.09 Million
Q4 2022

Feb 15, 2023

BUY
$4.92 - $7.4 $396,330 - $596,107
80,555 Added 80.35%
180,809 $987,000
Q3 2022

Nov 16, 2022

BUY
$4.52 - $6.51 $452,917 - $652,321
100,203 Added 196476.47%
100,254 $652,000
Q2 2022

Aug 16, 2022

BUY
$3.59 - $6.81 $50 - $95
14 Added 37.84%
51 $0
Q1 2022

May 16, 2022

BUY
$5.26 - $10.84 $194 - $401
37 New
37 $0
Q4 2021

Feb 14, 2022

SELL
$8.87 - $12.94 $1,516 - $2,212
-171 Closed
0 $0
Q3 2021

Nov 16, 2021

BUY
$12.21 - $17.2 $2,087 - $2,941
171 New
171 $2,000

Others Institutions Holding MXCT

About MAXCYTE, INC.


  • Ticker MXCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 101,724,000
  • Market Cap $451M
  • Description
  • MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...
More about MXCT
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.